MiMedx Group (MDXG) Expected to Announce Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is anticipated to release its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of ($0.0495) per share and revenue of $63.46 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $58.99 million for the quarter, compared to the consensus estimate of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. On average, analysts expect MiMedx Group to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $4.20 on Monday. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $3.86 and a two-hundred day simple moving average of $4.30. The firm has a market cap of $625.59 million, a PE ratio of 21.00 and a beta of 1.45. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.99.

Wall Street Analysts Forecast Growth

MDXG has been the topic of several research reports. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Citizens Jmp lowered their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Craig Hallum dropped their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Institutional Trading of MiMedx Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV raised its position in shares of MiMedx Group by 33.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock worth $141,000 after acquiring an additional 5,236 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in MiMedx Group by 116.2% during the second quarter. Tower Research Capital LLC TRC now owns 18,162 shares of the company’s stock valued at $111,000 after purchasing an additional 9,761 shares in the last quarter. AQR Capital Management LLC boosted its position in MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in MiMedx Group in the fourth quarter valued at about $105,000. Finally, Dark Forest Capital Management LP purchased a new position in MiMedx Group in the third quarter valued at about $104,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.